bioRxiv preprint doi: https://doi.org/10.1101/222406; this version posted November 22, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 BMPR2 inhibits activin- and BMP-signaling via wild type ALK2 2 3 Oddrun Elise Olsen1,2, Meenu Sankar3, Samah Elsaadi1, Hanne Hella1, Glenn Buene1, Sagar 4 Ramesh Darvekar1, Kristine Misund1,2, Takenobu Katagiri4 and Toril Holien1,2* 5 6 (1) Department of Clinical and Molecular Medicine, NTNU – Norwegian University of 7 Science and Technology, Trondheim, Norway. 8 (2) Clinic of Medicine, St. Olav’s University Hospital, Trondheim, Norway. 9 (3) School of Bioscience, University of Skövde, Skövde, Sweden. 10 (4) Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical 11 University, Hidaka-shi, Saitama 350-1241, Japan. 12 13 * Corresponding author 14 E-mail:
[email protected] 15 16 17 Running title: BMPR2 inhibits ALK2 activity 18 19 Key words: Bone Morphogenetic Protein, BMPR2, ACVR2A, ACVR2B, Activin, ACVR1 1 bioRxiv preprint doi: https://doi.org/10.1101/222406; this version posted November 22, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Summary Statement 2 The activation of SMAD1/5/8 via endogenous wild type ALK2 by activin A, activin B, and 3 certain BMPs was enhanced when BMPR2 levels were knocked down. 4 5 6 Abstract 7 Activin A is a member of the TGF-β superfamily and activates the transcription factors 8 SMAD2/3 through the ALK4 type 1 receptor.